본문 바로가기
KERD
논문KCI 등재

관상동맥 스텐트 삽입술을 시행한 환자에서 Omeprazole과의 병용이 Clopidogrel의 효능에 미치는 영향

The Clinical Outcome of Coadminstration of Clopidgrel and Omeprazole in patients undergoing coronary artery stent insertion

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

초록

Clopidogrel is converted to an active metabolite by hepatic cytochrome P450 isoenzymes,with cytochrome P450 2C19 (CYP2C19) playing a major role. Because omeprazole is the main substrate of this enzyme, the concomitant use of clopidogrel and omeprazole is associated with reduced plasma concentration of clopidogrel. However, there has been no definite conclusion yet to whether this drug-drug interaction results in significant clinical outcomes, such as cardiovascular events. Further, the expression rate of CYP2C19, which is a poor metabolizer, in Koreans is higher than in Caucasians. So this trial sought to assess the influence of omeprazole on clopidogrel efficacy in Korean patients. We conducted a retrospective study, among patients who received aspirin clopidogrel, following coronary artery stent insertion, between January 1, 2000, and December 31, 2008. ㄴWe performed a follow-up for a year after the surgical procedure and divided patients into two groups,the clopidogrel with omeprazole group (experimental group) and the clopidogrel alone group (control group). The former were 39 patients who take this combination therapy for more than a week, and the latter (at a ratio of 2:1) comprised of 65 patients that were matched to patients had with the same age, same sex, and no PPI history during the follow-up period. Date difference in the surgical procedure is within a year between the matched patients. We regarded the impact of omeprazole on clopidogrel efficacy as the frequency of the cardiovascular events, which are Major Adverse Cardiac Events and Stent Restenosis in Coronary Angiogram, during the follow-up period. Higher frequency appeared of these events in the clopidogrel,with omeprazole group, than in the clopidogrel alone group. However, there was no significant difference between the two groups. (35.9% vs 29.2%, p=0.48)In our study, co-administration of clopidogrel and omeprazole showed a negative effect on clopidogrel’s efficacy, but the result did not show statistical significance. Thereafter, a prospective study should be done in more patients in the near future.

Abstract

Clopidogrel is converted to an active metabolite by hepatic cytochrome P450 isoenzymes,with cytochrome P450 2C19 (CYP2C19) playing a major role. Because omeprazole is the main substrate of this enzyme, the concomitant use of clopidogrel and omeprazole is associated with reduced plasma concentration of clopidogrel. However, there has been no definite conclusion yet to whether this drug-drug interaction results in significant clinical outcomes, such as cardiovascular events. Further, the expression rate of CYP2C19, which is a poor metabolizer, in Koreans is higher than in Caucasians. So this trial sought to assess the influence of omeprazole on clopidogrel efficacy in Korean patients. We conducted a retrospective study, among patients who received aspirin clopidogrel, following coronary artery stent insertion, between January 1, 2000, and December 31, 2008. ㄴWe performed a follow-up for a year after the surgical procedure and divided patients into two groups,the clopidogrel with omeprazole group (experimental group) and the clopidogrel alone group (control group). The former were 39 patients who take this combination therapy for more than a week, and the latter (at a ratio of 2:1) comprised of 65 patients that were matched to patients had with the same age, same sex, and no PPI history during the follow-up period. Date difference in the surgical procedure is within a year between the matched patients. We regarded the impact of omeprazole on clopidogrel efficacy as the frequency of the cardiovascular events, which are Major Adverse Cardiac Events and Stent Restenosis in Coronary Angiogram, during the follow-up period. Higher frequency appeared of these events in the clopidogrel,with omeprazole group, than in the clopidogrel alone group. However, there was no significant difference between the two groups. (35.9% vs 29.2%, p=0.48)In our study, co-administration of clopidogrel and omeprazole showed a negative effect on clopidogrel’s efficacy, but the result did not show statistical significance. Thereafter, a prospective study should be done in more patients in the near future.

참고문헌 (8)

  1. 윤영란, "Clopidogrel in UnstableAngina to Prevent Recurrent Events TrialInvestigators; Effects of clopidogrel inaddition to aspirin in patients with acutecoronary syndromes without ST-segmentelevation", N Engl J Med, 345(7), pp.494~502 (2001)
  2. Simon T, "French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators, Genetic Determinants of Response to Clopidogreland Cardiovascular Event", N Engl J Med, 360(4), pp.363~375 (2009)
  3. Juurlink D.N, "A population- based study of the drug interaction between proton pump inhibitors and clopidogrel", CMAJ, 180(7), pp.713~718 (2009)
  4. Miao-Sibbing D, "Impact of proton pump inhibitors on antiplatelet effects of clopidogrel", Thromb Haemost, 101(4), pp.714~719 (2009)
  5. Gilard M, "Influence of omeprazole on the antiplatlet action of clopidogrel associated with aspirin ; the randomized, double-blind OCLA(Omeprazole Clopidogrel Aspirin Study)", J Am Coll Cardiol, 51(3), pp.256~260 (2008)
  6. Siller-Matula J.M, "Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel -Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel", Am Heart J, 157(1), pp.148~ (2008)
  7. 윤영란, "한국인의 Cytochrome P450 2C19 유전형 분석", 임상약리학회지, 10(1), pp.40~50 (2002), 대한임상약리학회
  8. J, Liu R, "Clopidogrel P-450 Polymorphisms and Response to Clopidogrel", N Engl J Med, 360(21), pp.2250~2251 (2009)

관련 논문AI추천

Influence of the Concomitant Use of Clopidogrel and Proton Pump Inhibitors on Adverse Cardiovascular Events in Korean Patients with Acute Coronary Syndrome김수현, 이유정한국임상약학회 · 한국임상약학회지2014 · 제24권 제2호관상동맥 스텐트 삽입술 시행 후 Clopidogrel 기반 이중 항혈소판 치료를 받는 환자에서 Esomeprazole과 Tegoprazan 병용 및 심혈관계 사건 발생 비교고종희, 김재송, 류하빈, 손은선, 유윤미, 이희원한국병원약사회 · 병원약사회지2024 · 제41권 제2호항혈소판제제와 프로톤펌프억제제 간의 약물 상호 작용:Unsafe 측면과 대책이경훈, 한승환대한내과학회 · 대한내과학회지2011 · 제81권 제1호Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea윤혁, 김나영, 남령희, 박영수, 박지현, 신철민, 이동호, 장인진, 정현채, 조주연, 조현진, 최윤진거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제4호허혈성 심장 환자에서 프로톤펌프억제제와 Clopidogrel 병용투여 효과박일, 고광현, 권창일, 김도형, 김용훈, 김원희, 박필원, 이중민, 임규성, 정준구, 홍성표, 황성규대한내과학회 · 대한내과학회지2011 · 제80권 제4호항혈소판제제를 포함한 약물상호작용에 미치는 프로톤펌프억제제의 영향: Safe 측면조윤주대한내과학회 · 대한내과학회지2011 · 제81권 제1호

이 간행물의 다른 논문 (7건)